Fosfocreatine

Summary

Fosfocreatine (CHEMBL1204644) is a phase-3 clinical-stage small molecule (ATC C01EB06); indicated across 2 conditions including cardiovascular disorder and major depressive disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: C01EB06
• Indications: 2 conditions
• Clinical trials: 4
• Chemistry: 211.11 Da · C4H10N3O5P

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1204644
Name	Fosfocreatine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	9548602
ChEBI	CHEBI:17287
ATC	C01EB06
Molecular formula	C4H10N3O5P
Molecular weight	211.11
InChIKey	DRBBFCLWYRJSJZ-UHFFFAOYSA-N

SMILES: CN(CC(=O)O)/C(=N/P(=O)(O)O)/N

IUPAC name: 2-[methyl-[(E)-N’-phosphonocarbamimidoyl]amino]acetic acid

ChEBI definition: A phosphoamino acid consisting of creatine having a phospho group attached at the primary nitrogen of the guanidino group.

Other ChEBI roles (chemical / environmental): human metabolite, mouse metabolite.

Also known as: Creatine phosphate, Creatine-p, Fosfocreatine, Phosphagen, Phosphocreatine, FOSFOCREATINE

Parent form; salt/anhydrous children: CHEMBL7649

Patent coverage: 6,030 distinct patent families (14,903 SureChEMBL compound mentions), from 4 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
cardiovascular disorder	3	MONDO:0004995	EFO:0000319
major depressive disorder	2	MONDO:0002009	MONDO:0002009

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE3	2
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06503016	PHASE3	RECRUITING	The Effect of phoSPHocreatine on mEdical Emergency Team (Met) tREated Patients
NCT02757443	PHASE3	COMPLETED	Myocardial Protection With Phosphocreatine in High-RIsk Cardiac SurgEry Patients
NCT03138681	PHASE2	UNKNOWN	Rapid Antidepressant Effects of ATP and Phosphocreatine
NCT05431413	PHASE2	UNKNOWN	Rapid Improvement of Depression of Fluoxetine Combined With ATP

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).